The ChinaAMC Hang Seng Healthcare ETF (03069) has risen more than 3%. This ETF tracks the Hang Seng Biotechnology Index, which includes a portfolio of leading, globally competitive Chinese biotech firms such as Kangfang Biotech, Xinda Biotech, and BeiGene. As of the latest update, the ETF is up 3.23% to HKD 12.46, with a trading volume of HKD 122 million.

Market Drivers for the Innovative Drug Sector

The innovative drug sector in Hong Kong stocks saw another uptick today. According to analysis from Industrial Securities, recent data readouts for several innovative drugs have met or slightly exceeded market expectations, significant business development deals have been announced one after another, and event-driven catalysts are continuous, all of which have enhanced the sector's valuation appeal. The sector is currently transitioning from being driven by "valuation" to being driven by "performance + global realization." As business development candidates advance into overseas Phase III trials, their likelihood of approval and commercialization increases, potentially further boosting projected peak sales and success rates. In the long term, there is optimism for innovative drug companies that possess differentiated innovation capabilities, potential for global best-in-class products, and the ability to scale up single-product sales.